Metastatic pancreatic cancer still represent one of the most deadly disease for
which there are few therapeutic options, especially in second line and beyond setting. Nabpaclitaxel
plus gemcitabine activity was demonstrated in first line setting, but there are
no clear evidence suggesting its use after that. We report a retrospective data analysis
of 23 patients who received nab-paclitaxel plus gemcitabine after first line treatment at our
Oncology Department. We observed a significant clinical benefit (43,5%) with a median
overall survival of 5 months. In addition, manageable side effects were reported.
Our data, despite the small sample, seem to indicate that nab- paclitaxel plus gemcitabine is an active and
well tolerated regimen even in pretreated patients.
Keywords: CA19.9, clinical benefit, gemcitabine, metastatic pancreatic cancer, nab- paclitaxel.
Rights & PermissionsPrintExport